Roche announced today that the World Health Organization (WHO) has awarded the cobas® HPV test prequalification designations for use on the cobas® 5800 system and for self-collected samples on the cobas® 5800, 6800 and 8800 systems. These new prequalification designations come…
Roche announced that its Elecsys pTau217 assay received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This blood test, which is being developed in collaboration with Eli Lilly and Company, will be used to help identify the…
Nazli Sahafi has been appointed as the General Manager of Roche Diagnostics Türkiye, Head of the Türkiye, Central Asia and Caucasian Countries Management Center, as of April 1, 2024. Nazli Sahafi, who started her career as a researcher and scientist…
Roche announced the U.S. Food and Drug Administration (FDA) approval of the cobas® Malaria test for use on the cobas® 6800/8800 Systems. This approved test can aid healthcare professionals in reducing potential risks of patient infection from transfused blood products.…
Roche announced the entry into a definitive agreement to acquire select parts of the LumiraDx group related to LumiraDx’s innovative Point of Care technology. Following closing of the transaction, which is expected by mid-2024, the acquired entities will be fully…
Roche today announced the launch of Elecsys® HBeAg quant, an immunoassay that is able to determine both the presence and quantity (qualitative and quantitative) of the hepatitis B e antigen (HBeAg) in human serum and plasma. This launch means that,…
Roche announced today that the Elecsys IL-6 immunoassay has become the first IL-6 test to have a certified claim for use in diagnosis of neonatal sepsis, in countries accepting the CE Mark. Elecsys IL-6 aids physicians in combating the impact…